Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker ARWR
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Michael S. Perry Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 11,600 | $87.30 | $1.0M Sale | Form 4 ↗ |
| Aug 18, 2026 | Adeoye Y. Olukotun Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 2,000 | $86.96 | $173.9K Sale | Form 4 ↗ |
| May 12, 2026 | Hongbo Lu Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 2,970 | $76.88 | $228.3K Sale | Form 4 ↗ |
| Apr 23, 2026 | James C. Hamilton Chief Medical Officer | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 10,000 | $75.00 | $750.0K Sale | Form 4 ↗ |
| Apr 22, 2026 | Daniel Joseph Apel Chief Financial Officer | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 8,730 | $71.92 | $627.9K Sale | Form 4 ↗ |
| Apr 22, 2026 | Daniel Joseph Apel Chief Financial Officer | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 1,157 | $70.45 | $81.5K Sale | Form 4 ↗ |
| Apr 22, 2026 | Daniel Joseph Apel Chief Financial Officer | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 3,208 | $70.11 | $224.9K Sale | Form 4 ↗ |
| Mar 5, 2026 | James C. Hamilton Chief Medical Officer | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 10,000 | $64.19 | $641.9K Sale | Form 4 ↗ |
| Jan 5, 2026 | James C. Hamilton Chief Medical Officer | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 309 | $68.00 | $21.0K Sale | Form 4 ↗ |
| Jan 5, 2026 | James C. Hamilton Chief Medical Officer | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 437 | $65.97 | $28.8K Sale | Form 4 ↗ |
| Jan 5, 2026 | James C. Hamilton Chief Medical Officer | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 1,200 | $64.49 | $77.4K Sale | Form 4 ↗ |
| Jan 5, 2026 | James C. Hamilton Chief Medical Officer | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 12,711 | $63.95 | $812.9K Sale | Form 4 ↗ |
| Jan 5, 2026 | James C. Hamilton Chief Medical Officer | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 14,792 | $63.01 | $932.0K Sale | Form 4 ↗ |
| Jan 5, 2026 | James C. Hamilton Chief Medical Officer | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 6,090 | $62.28 | $379.3K Sale | Form 4 ↗ |
| Jan 5, 2026 | James C. Hamilton Chief Medical Officer | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 4,625 | $61.24 | $283.2K Sale | Form 4 ↗ |
| Jan 5, 2026 | Patrick O'Brien COO | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 46 | $68.00 | $3,128 Sale | Form 4 ↗ |
| Jan 5, 2026 | Patrick O'Brien COO | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 2,336 | $64.04 | $149.6K Sale | Form 4 ↗ |
| Jan 5, 2026 | Patrick O'Brien COO | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 5,873 | $62.91 | $369.5K Sale | Form 4 ↗ |
| Jan 5, 2026 | Patrick O'Brien COO | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 900 | $62.25 | $56.0K Sale | Form 4 ↗ |
| Jan 5, 2026 | Patrick O'Brien COO | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 600 | $61.12 | $36.7K Sale | Form 4 ↗ |
| Jan 5, 2026 | Patrick O'Brien COO | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 313 | $68.00 | $21.3K Sale | Form 4 ↗ |
| Jan 5, 2026 | Patrick O'Brien COO | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 900 | $66.01 | $59.4K Sale | Form 4 ↗ |
| Jan 5, 2026 | Patrick O'Brien COO | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 2,700 | $64.44 | $174.0K Sale | Form 4 ↗ |
| Jan 5, 2026 | Patrick O'Brien COO | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 11,842 | $63.84 | $756.0K Sale | Form 4 ↗ |
| Jan 5, 2026 | Patrick O'Brien COO | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 13,451 | $62.96 | $846.9K Sale | Form 4 ↗ |
| Jan 5, 2026 | Patrick O'Brien COO | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 6,164 | $62.23 | $383.6K Sale | Form 4 ↗ |
| Jan 5, 2026 | Patrick O'Brien COO | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 4,368 | $61.20 | $267.3K Sale | Form 4 ↗ |
| Jan 2, 2026 | Christopher Richard Anzalone Chief Executive Officer, Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 5,771 | $66.39 | $383.1K Sale | Form 4 ↗ |
| Jan 2, 2026 | Christopher Richard Anzalone Chief Executive Officer, Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 7,416 | $65.88 | $488.6K Sale | Form 4 ↗ |
| Dec 29, 2025 | Christopher Richard Anzalone Chief Executive Officer, Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 16,545 | $68.69 | $1.1M Sale | Form 4 ↗ |
| Dec 29, 2025 | Christopher Richard Anzalone Chief Executive Officer, Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 35,181 | $69.33 | $2.4M Sale | Form 4 ↗ |
| Dec 26, 2025 | Mauro Ferrari Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 7,530 | $70.00 | $527.1K Sale | Form 4 ↗ |
| Dec 22, 2025 | Christopher Richard Anzalone Chief Executive Officer, Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 2,574 | $68.85 | $177.2K Sale | Form 4 ↗ |
| Dec 22, 2025 | Christopher Richard Anzalone Chief Executive Officer, Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 10,012 | $68.33 | $684.1K Sale | Form 4 ↗ |
| Dec 19, 2025 | Victoria Vakiener Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 1,960 | $68.39 | $134.0K Sale | Form 4 ↗ |
| Dec 19, 2025 | Victoria Vakiener Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 5,281 | $67.97 | $358.9K Sale | Form 4 ↗ |
| Dec 19, 2025 | Victoria Vakiener Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 2,799 | $66.63 | $186.5K Sale | Form 4 ↗ |
| Dec 19, 2025 | William D. Waddill Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 500 | $68.53 | $34.3K Sale | Form 4 ↗ |
| Dec 19, 2025 | William D. Waddill Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 5,451 | $68.01 | $370.7K Sale | Form 4 ↗ |
| Dec 19, 2025 | William D. Waddill Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 2,416 | $66.66 | $161.1K Sale | Form 4 ↗ |
| Dec 19, 2025 | Christopher Richard Anzalone Chief Executive Officer, Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 1,319 | $68.48 | $90.3K Sale | Form 4 ↗ |
| Dec 19, 2025 | Christopher Richard Anzalone Chief Executive Officer, Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 8,147 | $68.01 | $554.1K Sale | Form 4 ↗ |
| Dec 19, 2025 | Christopher Richard Anzalone Chief Executive Officer, Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 3,979 | $66.67 | $265.3K Sale | Form 4 ↗ |
| Dec 19, 2025 | Adeoye Y. Olukotun Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 827 | $68.48 | $56.6K Sale | Form 4 ↗ |
| Dec 19, 2025 | Adeoye Y. Olukotun Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 6,083 | $68.04 | $413.9K Sale | Form 4 ↗ |
| Dec 19, 2025 | Adeoye Y. Olukotun Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 3,090 | $66.70 | $206.1K Sale | Form 4 ↗ |
| Dec 17, 2025 | Christopher Richard Anzalone Chief Executive Officer, Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 1,981 | $66.30 | $131.3K Sale | Form 4 ↗ |
| Dec 17, 2025 | Christopher Richard Anzalone Chief Executive Officer, Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 982 | $65.53 | $64.4K Sale | Form 4 ↗ |
| Dec 17, 2025 | Christopher Richard Anzalone Chief Executive Officer, Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 35,750 | $64.51 | $2.3M Sale | Form 4 ↗ |
| Dec 17, 2025 | Christopher Richard Anzalone Chief Executive Officer, Director | ARWR Arrowhead Pharmaceuticals, Inc. | Sale | 46,287 | $63.55 | $2.9M Sale | Form 4 ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:50 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances